Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: C01EB25

Beyonttra(acoramidis hydrochloride)

Amyloid Neuropathies, Familial

Marketing Authorisation Holder: Bayer AG

EMA Authorisation: 10/02/2025

INN: acoramidis

Indication

For the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Beyonttra — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.